MA44550B1 - Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés - Google Patents

Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés

Info

Publication number
MA44550B1
MA44550B1 MA44550A MA44550A MA44550B1 MA 44550 B1 MA44550 B1 MA 44550B1 MA 44550 A MA44550 A MA 44550A MA 44550 A MA44550 A MA 44550A MA 44550 B1 MA44550 B1 MA 44550B1
Authority
MA
Morocco
Prior art keywords
cell wall
teichoic acid
wall anti
acid antibodies
conjugates
Prior art date
Application number
MA44550A
Other languages
English (en)
Other versions
MA44550A1 (fr
Inventor
Richard Vandlen
Martine Darwish
John Flygare
Wouter Hazenbos
Byoung-Chul Lee
Sanjeev Mariathasan
Klaus Koefoed
Magnus Strandh
Sophie Lehar
John Morisaki
Thomas Pillow
Leanna Staben
Peter Andersen
Eric Brown
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority claimed from PCT/US2014/040324 external-priority patent/WO2014194247A1/fr
Publication of MA44550A1 publication Critical patent/MA44550A1/fr
Publication of MA44550B1 publication Critical patent/MA44550B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

La présente invention concerne des anticorps anti-acide téichoïque de la paroi cellulaire et leurs conjugués antibiotiques, ainsi que leurs méthodes d'utilisation.
MA44550A 2013-05-31 2014-05-30 Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés MA44550B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829461P 2013-05-31 2013-05-31
US14/284,609 US20140356375A1 (en) 2013-05-31 2014-05-22 Anti-wall teichoic antibodies and conjugates
PCT/US2014/040324 WO2014194247A1 (fr) 2013-05-31 2014-05-30 Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés

Publications (2)

Publication Number Publication Date
MA44550A1 MA44550A1 (fr) 2019-06-28
MA44550B1 true MA44550B1 (fr) 2021-06-30

Family

ID=50983181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44550A MA44550B1 (fr) 2013-05-31 2014-05-30 Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés

Country Status (4)

Country Link
US (1) US20140356375A1 (fr)
AR (1) AR096388A1 (fr)
MA (1) MA44550B1 (fr)
TW (2) TWI632157B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884126B2 (en) 2013-05-31 2018-02-06 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
NZ720743A (en) 2013-12-16 2021-12-24 Medimmune Ltd Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082875B1 (fr) 2013-12-16 2020-11-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
MX2016010799A (es) * 2014-02-19 2017-01-23 Texas A & M Univ Sys Composiciones para sensibilizacion a farmaco de parasitos.
MX2017007055A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017152083A1 (fr) * 2016-03-04 2017-09-08 Genentech, Inc. Procédé de préparation d'un conjugué anticorps-rifamycine
WO2017156458A1 (fr) 2016-03-11 2017-09-14 University Of South Florida Inhibiteurs de bêta-lactamases, formulations et utilisations correspondantes
CN113226470A (zh) 2018-12-21 2021-08-06 瑞泽恩制药公司 利福霉素类似物及其抗体-药物缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2507711A1 (fr) * 2002-12-02 2004-06-17 Biosynexus Incorporated Acide teichoique a paroi en tant que cible pour therapies et vaccins anti-staphylococciques
ES2697327T3 (es) * 2003-11-06 2019-01-23 Seattle Genetics Inc Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador

Also Published As

Publication number Publication date
MA44550A1 (fr) 2019-06-28
US20140356375A1 (en) 2014-12-04
AR096388A1 (es) 2015-12-30
TWI632157B (zh) 2018-08-11
TWI692483B (zh) 2020-05-01
TW201524997A (zh) 2015-07-01
TW201839012A (zh) 2018-11-01

Similar Documents

Publication Publication Date Title
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
MA44550B1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MA34881B1 (fr) Anticorps et immunoconjugués anti-mésothéline
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA44637A1 (fr) Composes hétérocycliques et leurs utilisations
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA34521B1 (fr) Polypeptides de relaxine modifiés et leurs utilisations
MX2021015825A (es) Formulaciones de anticuerpos estables acuosas.
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
MY161868A (en) Anti-bv8 antibodies and uses thereof
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MA39126A2 (fr) Synthèse d'enantiomère de progestérone et d'intermédiaires de celui-ci
MA39355B2 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants